Elite Pharmaceuticals Inc /de/
Elite Pharmaceuticals Inc /de/ is listed today as Elite Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2009 | $1 M | A long-registered or listed company | Under $2 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Elite Pharmaceuticals, Inc., its revenue in fiscal 2026 came from these product and service lines: Manufacturing $147.81 million (99%), Manufacturing Fees $147.81 million (99%), Scheduled Products Manufacturing Fees $141.47 million (95%), Indirect Sales to Wholesalers $82.54 million (55%), Direct Sales to Wholesalers $65.27 million (44%).
Annual report (SEC XBRL) · Mar 2026
Elite Pharmaceuticals Inc /de/ chose not to state its revenue in its newest notice of a funding round (Jun 2009).
SEC Form D · Jun 2009
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jun 2009
Products and services#
No products or services of Elite Pharmaceuticals Inc /de/ are on record.
Investors#
No investor of Elite Pharmaceuticals Inc /de/ is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Chris Dick | Executive officer | Jun 2009 |
| Mark Gittelman | Executive officer | Jun 2009 |
| Barry Dash | Director | Jun 2009 |
| Chris Dick | Director | Jun 2009 |
| Jerry Treppel | Director | Jun 2009 |
| Melvin Van Woert | Director | Jun 2009 |
| Robert J. Levenson | Director | Jun 2009 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.